Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
January 25, 2018
Albireo Prices $65.0 Million Public Offering of Common Stock
BOSTON, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today ...
January 25, 2018
OSE Immunotherapeutics Receives Notice of Allowance for New Patent by U.S. Patent and Trademark Office that Further Strengthens Intellectual Property Portfolio Around Tedopi® in Immuno-Oncology Applications
NANTES, France, Jan. 25, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics(ISIN:FR0012127173) (Mnémo:OSE), today announces that it has received a notice of allowance from the U.S. Patent ...
January 25, 2018
Zealand Pharma hosts Capital Market Day: Accelerating the late stage pipeline
Copenhagen 25 January, 2018 - Zealand Pharma (Zealand) will host a Capital Market Day in New York, starting at 12:30 pm ET (6.30 pm CET), ...
January 23, 2018
BioTime to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference in Fort Lauderdale, January 29, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief ...
January 23, 2018
BioCanCell Announces Terms of $25 Million Funding Round
JERUSALEM, Jan. 23, 2018 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL) (the “Company"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel ...
January 23, 2018
Altimmune Announces Notice of Allowance on Patent Covering Use of NasoShield in the U.S.
GAITHERSBURG, Md., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced that it has received a Notice of Allowance ...
January 23, 2018
New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome (SBS)
Copenhagen, Denmark, January 23, 2018 - Zealand Pharma ("Zealand") reports that the PK profile of their long-acting GLP-2 analog, glepaglutide, supports once- or twice-weekly dosing ...
January 23, 2018
Zealand Pharma to present Phase 2 results on glepaglutide at the ASPEN 2018 Conference in Las Vegas, U.S.
Copenhagen, January 23, 2018 - Zealand Pharma (Zealand) and Rahim M. Naimi, MD, Department of Gastroenterology, Rigshospitalet, University of Copenhagen, Denmark, will present Phase 2 key ...
January 22, 2018
BioTime Announces Clinical and Corporate Milestone Targets for 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced its 2018 clinical and ...
January 22, 2018
Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting
ROCKVILLE, Md., Jan. 22, 2018 (GLOBE NEWSWIRE) --  Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment ...
January 22, 2018
Altimmune to Participate at the Noble Capital 14th Annual Investor Conference
GAITHERSBURG, Md., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, ...
January 22, 2018
AIT Therapeutics Announces Further Data From Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) Patients
NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the ...
January 19, 2018
Aeglea BioTherapeutics to Present Preclinical Data at 2018 Keystone Symposia Tumor Metabolism Conference
AUSTIN, Texas, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (AGLE), a biotechnology company committed to the discovery and development of engineered human enzyme ...
January 19, 2018
Reata Announces the Publication of Efficacy Data From the Beacon Study of Bardoxolone in Diabetic CKD in the American Journal of Nephrology
IRVING, Texas, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company, today announced the digital publication of ...
January 19, 2018
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares
RA'ANANA, Israel and NEW YORK, Jan. 18, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs ...
January 19, 2018
HTG Molecular Diagnostics Announces Pricing of Public Offering of Common Stock
TUCSON, Ariz., Jan. 18, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, ...
January 19, 2018
Santhera Plans to Announce Regulatory Feedback for Raxone® in DMD and 2017 Preliminary Key Financial Figures
Liestal, Switzerland, January 19, 2018 - Santhera Pharmaceuticals (SANN.SW) expects to announce feedback from the CHMP on its Marketing Authorization Application (MAA) for Raxone® in Duchenne ...
January 19, 2018
Zealand Pharma strengthens its Management by appointing Ivan Møller as SVP, Technical Development & Operations
Copenhagen, Denmark, January 19, 2018 - Zealand Pharma A/S ("Zealand") announces the appointment of Ivan Møller to a new position as Senior Vice President, Technical ...
January 18, 2018
AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD for Exocrine Pancreatic Insufficiency
BROOKLYN, N.Y., Jan. 18, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant ...
January 18, 2018
Vermillion Announces Agreement with BlueCross BlueShield of Illinois
AUSTIN, Texas, Jan. 18, 2018 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (VRML) and exclusive distributor of OVA1 (Multivariate Index Assay, or MIA), an ovarian cancer ...
Page 70 of 117